Zenith Drugs Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹35(44.30%)
Premium (ELP)
Zenith Drugs Limited's successfully transitioned to public market status with its listing on NSE on Feb 27, 2024. The IPO mobilized 51,48,800 Shares in cumulative capital, including 51,48,800 Shares for corporate expansion.
The public offering was conducted within the price parameters of ₹75 to ₹79, with minimum investment lots of 1600 shares. subscription activity between Feb 19, 2024 and Feb 22, 2024 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on Feb 23, 2024, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Zenith Drugs Limited, founded in 2000, is a pharmaceutical company that manufactures and trades affordable, high-quality medicines, including various generic products. The company operates under WHO-GMP guidelines and holds an ISO 9001:2015 certification, reflecting its focus on quality. It offers a wide product range such as ORS powder, liquid orals, ointments, liquid externals, and capsules, with over 600 products approved by the Food & Drugs Administration and 325 currently in production. Zenith Drugs is expanding by setting up a new manufacturing facility in Muradpura, Depalpur, Indore, and it also exports its products to multiple regions including Central America, Africa, Southeast Asia, and South Asia. The company provides third-party manufacturing services to well-known pharmaceutical brands like Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, and as of March 31, 2023, it employs 89 people, including both payroll and contract staff.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Experienced Leadership: The company is guided by seasoned promoters and a skilled management team, ensuring strong leadership and strategic growth.
- Cost Efficiency: A focus on cost-effective operations helps maximize resource use, boosting profitability and competitiveness.
- Innovation & Development: Strong formulation and development capabilities allow the company to innovate and adapt to market trends, setting it apart from competitors.
- Regulatory Compliance: Strict adherence to regulations ensures smooth operations, reduces risks, and strengthens the company’s reputation.
- Global Presence: A broad international market reach helps diversify revenue streams and reduces reliance on any single region.
- Restrictive Financing Conditions: The company must get lender approval for financial decisions like borrowing or restructuring, which may limit flexibility in operations.
- Raw Material & Supplier Dependency: Relying on key suppliers without long-term contracts poses a risk—any shortages or price hikes could impact production and profitability.
- Manufacturing & Quality Risks: Any issues in production or quality control could disrupt operations, harm the company’s reputation, and lead to potential legal challenges.
- Rising Competition: Failure to keep up with increasing competition could result in lower market share and reduced profitability.
- Customer Payment Delays: Late or missed payments from customers could strain cash flow, affecting daily operations and financial stability.
- Mr. Sandeep Bhardwaj
- Mr. Bhupesh Soni
- Mr. Ajay Singh Dassundi
Zenith Drugs Limited
Bigshare Services Private Limited